Despite A Downgrade, Vetr Still Bullish On Vertex

On Wednesday, the Vetr crowd downgraded its rating of Vertex Pharmaceuticals Incorporated VRTX from its previous standing of 4.5 stars (Strong Buy) issued earlier this week, to four stars (Buy). Crowd confidence in Vertex is still overwhelmingly positive, with 100 percent of Vetr users bullish toward the stock.

Following last week's reaction to President-elect Donald Trump's comments on lowing drug prices, Vertex's price experienced slight fluctuation, but no monumental change.

However, the post-election biotech bump has certainly settled into a more standard formation. By 1 p.m. on Wednesday, Vertex was hovering at around $77.30, pretty close to its price early in November.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $85.33, which is well below the average analyst price of $108.68. Less than 2 percent of Vetr users are holding Vertex on their watch-lists.